Compare Fox Corp Class B (FOX) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fox Corp Class B vs Natera Inc. Common Stock — how do they compare? Fox Corp Class B trades at $55.56 (market cap $24.91B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 2.3× Fox Corp Class B's market cap, and Fox Corp Class B pays a 1.04% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fox Corp Class B for 75 Days and Natera Inc. Common Stock for 0 Days on average.
| FOX | NTRA | |
|---|---|---|
Market Cap | $24.91B | $57.03B |
Volume | 395,394 | 1,131,157 |
Sector | Media | Health |
52-Week High | $67.76 | $425.64 |
52-Week Low | $44.39 | $179.42 |
Typical Hold Time | 75 Days | 0 Days |
Enterprise Value | $28.27B | $56.18B |
Dividend Yield | 1.04% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FOX trades at $55.68, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.79 exceeding the $1.44 estimate. Fundamentals show robust revenue growth to $16.30 billion in 2025 and a net income margin of 13.88%. Analyst consensus is a Buy with a $84.75 price target, implying significant upside, though cash flow projections for 2026 indicate a potential net outflow.
The outlook for FOX is positive based on solid fundamentals and analyst optimism, but risks include a projected net cash flow deficit in 2026 and competitive pressures in the media sector. The stock presents a value opportunity with a P/E of 14.56 trading below the analyst target, yet investors should monitor execution against future earnings expectations and industry headwinds.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Fox Corp Class B
Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.
Read more on FOX →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
